Pembrolizumab + CT peri-op

With the OS benefit of Checkmate 816 and the lack of comparative studies, the adjuvant portion is gonna be a challenging issue. An indirect meta-analysis suggested that adjuvant post neoadjuvant « may not improve survival outcomes for patients with resectable NSCLC and may be associated with increased adverse events » adding to the high financial toxicity and the burden of months of therapy on the healthcare system.

Following INESSS’s negative recommendation, PSP closed in Quebec.

Two publications worth a read :

Adjuvant IO should not be used for patients who obtain pCR vs Adjuvant IO should be used for patients who obtain pCR

And finally a nice summary for NA, A and perioperative strategies in resectable NSCLC